Compare Brown-Forman Corporation Class B (BF.B) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brown-Forman Corporation Class B vs Citius Pharmaceuticals Inc — how do they compare? Brown-Forman Corporation Class B trades at $28.01, while Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M). The key difference: Brown-Forman Corporation Class B is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| BF.B | CTXR | |
|---|---|---|
Sector | Consumer Staples | Health |
52-Week High | $31.26 | $1.82 |
52-Week Low | $22.80 | $0.48 |
Market Cap | — | $18.73M |
Enterprise Value | — | $14.95M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BF.B trades at $28.52, up 0.88% today, with a bullish technical signal from moving averages and strong trend strength (ADX). Earnings have beaten estimates in three of the last four quarters, with Q2 2024 EPS of $0.48 exceeding the $0.46 forecast. The stock faces mixed analyst sentiment but shows consistent fundamental performance.
The outlook is cautiously optimistic given recent earnings strength, though limited analyst coverage and mixed ratings suggest uncertainty. Key risks include execution challenges and market volatility. Upside potential hinges on sustained earnings growth and broader market conditions.
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brown-Forman Corporation Class B
Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.
Read more on BF.B →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
